Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Heard

Showing results (61-70 of 73) with videos related to

Pageof 8
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2003
Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectantNeal J Meropol, Robert A Somer, John Gutheil, et al.
International Journal of Speech-Language Pathology|February 27, 2020
Simulation can replace part of speech-language pathology placement time: A randomised controlled trialAnne E Hill, Elizabeth Ward, Robert Heard, et al.
Academic Radiology|August 29, 2018
Toward Improving Breast Cancer Imaging: Radiological Assessment of Propagation-Based Phase-Contrast CT TechnologySeyedamir Tavakoli Taba, Patrycja Baran, Sarah Lewis, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|July 3, 2014
Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 2 new and emerging therapies and their efficacy. MS Neurology Group of the Australian and New Zealand Association of NeurologistsSimon A Broadley, Michael H Barnett, Mike Boggild, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|July 5, 2014
Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 1 historical and established therapies. MS Neurology Group of the Australian and New Zealand Association of NeurologistsSimon A Broadley, Michael H Barnett, Mike Boggild, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|July 5, 2014
Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 3 treatment practicalities and recommendations. MS Neurology Group of the Australian and New Zealand Association of NeurologistsSimon A Broadley, Michael H Barnett, Mike Boggild, et al.
The Medical Journal of Australia|July 31, 2015
A new era in the treatment of multiple sclerosisSimon A Broadley, Michael H Barnett, Mike Boggild, et al.
American Journal of Human Genetics|August 5, 2005
A high-density screen for linkage in multiple sclerosisStephen Sawcer, Maria Ban, Mel Maranian, et al.
Journal of Neuroimmunology|August 29, 2006
Linkage disequilibrium screening for multiple sclerosis implicates JAG1 and POU2AF1 as susceptibility genes in Europeans, Maria Ban, David Booth, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 28, 2017
Incidence and prevalence of NMOSD in Australia and New ZealandWajih Bukhari, Kerri M Prain, Patrick Waters, et al.
Pageof 8

Showing results (61-70 of 73) with videos related to

Sort By:
Pageof 8
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2003
Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectantNeal J Meropol, Robert A Somer, John Gutheil, et al.
International Journal of Speech-Language Pathology|February 27, 2020
Simulation can replace part of speech-language pathology placement time: A randomised controlled trialAnne E Hill, Elizabeth Ward, Robert Heard, et al.
Academic Radiology|August 29, 2018
Toward Improving Breast Cancer Imaging: Radiological Assessment of Propagation-Based Phase-Contrast CT TechnologySeyedamir Tavakoli Taba, Patrycja Baran, Sarah Lewis, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|July 3, 2014
Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 2 new and emerging therapies and their efficacy. MS Neurology Group of the Australian and New Zealand Association of NeurologistsSimon A Broadley, Michael H Barnett, Mike Boggild, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|July 5, 2014
Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 1 historical and established therapies. MS Neurology Group of the Australian and New Zealand Association of NeurologistsSimon A Broadley, Michael H Barnett, Mike Boggild, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|July 5, 2014
Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 3 treatment practicalities and recommendations. MS Neurology Group of the Australian and New Zealand Association of NeurologistsSimon A Broadley, Michael H Barnett, Mike Boggild, et al.
The Medical Journal of Australia|July 31, 2015
A new era in the treatment of multiple sclerosisSimon A Broadley, Michael H Barnett, Mike Boggild, et al.
American Journal of Human Genetics|August 5, 2005
A high-density screen for linkage in multiple sclerosisStephen Sawcer, Maria Ban, Mel Maranian, et al.
Journal of Neuroimmunology|August 29, 2006
Linkage disequilibrium screening for multiple sclerosis implicates JAG1 and POU2AF1 as susceptibility genes in Europeans, Maria Ban, David Booth, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 28, 2017
Incidence and prevalence of NMOSD in Australia and New ZealandWajih Bukhari, Kerri M Prain, Patrick Waters, et al.
Pageof 8